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Abstract
Background: Complicated skin and soft tissue infections (cSSTIs) are a major clinical problem, in part because
of the increasing resistance of infecting bacteria to our current antibiotic therapies. Prompt appropriate treat-
ment of infections in hospitalized patients reduces the mortality rate. Furthermore, appropriate and timely an-
tibiotic therapy improves outcomes for cSSTIs caused by methicillin-resistant Staphylococcus aureus (MRSA).
This review delineates factors to consider in the choice of initial antibiotic treatment for cSSTIs and describes
the antimicrobial agents available or under clinical development for the treatment of cSSTIs caused by MRSA.
Methods: Review of the pertinent literature and recommendations.
Results: The choice of antimicrobial agent for empiric treatment of cSSTIs should be guided by the site and
type of infection, the presence of an immunocompromised state or neutropenia, and risk factors for hospital-
acquired MRSA (HA-MRSA) or community-associated MRSA (CA-MRSA) infection. Most CA-MRSA strains
remain susceptible to ciprofloxacin, clindamycin, gentamicin, and trimethoprim/sulfamethoxazole, although
resistance to clindamycin can emerge during treatment. Of the agents available for the treatment of HA-MRSA
cSSTIs, vancomycin has been the reference standard, but clinical failures have been reported increasingly. Al-
ternative agents for HA-MRSA include linezolid, which has been well-studied for treatment of cSSTIs, as well
as daptomycin and tigecycline. A number of antibiotic agents are undergoing clinical trials or are under de-
velopment for the treatment of cSSTIs caused by MRSA.
Conclusions: Severe and progressive cSSTIs should be treated promptly with appropriate antibiotic agents. The
choice of agent should be guided by a number of factors, including suspected CA-MRSA or HA-MRSA infec-
tion. Available agents should be evaluated carefully for efficacy in the treatment of MRSA cSSTIs.
S-17
THE INITIAL MANAGEMENT of complicated skin and soft tis-sue infections (cSSTIs) should include the collection of
specimens for culture and antimicrobial susceptibility testing
from all abscesses or purulent lesions [1]. Culture and sus-
ceptibility findings are useful both for individual patient
management and for monitoring of local patterns of anti-
microbial resistance [1]. Physicians and other healthcare
workers cannot predict accurately if an SSTI is attributable to
methicillin-resistant Staphylococcus aureus (MRSA) [2]. A
prospective observational study of 176 emergency depart-
ment patients presenting with purulent wounds and ab-
scesses documented that physician suspicion of MRSA had a
sensitivity of only 80% (95% confidence interval [CI], 71, 87)
and a specificity of 23.6% (95% CI 14, 37) for the presence of
MRSA on wound culture, with a positive likelihood ratio (LR)
of 1.0 (95% CI 0.9, 1.3) and a negative LR of 0.8 (95% CI 0.5,
1.3). The prevalence of such infections was 64% [2].
The research reviewed in this paper demonstrates that
timely and appropriate empiric antibiotic therapy improves
the outcomes of patients with serious infections, including
SSTIs caused by MRSA [3,4]. Empiric antibiotic therapy
should be initiated in all patients with cSSTIs. Intravenous
(IV) broad-spectrum antimicrobial therapy should be given
when an infection is severe or progresses rapidly, when there
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are signs of systemic illness, when the patient has co-mor-
bidities or is immunosuppressed, when the patient is very
old or young, when an abscess cannot be drained completely,
or when the infection does not respond to incision and
drainage [1]. A number of antimicrobial agents are now
available for the treatment of cSSTIs caused by MRSA. This
paper discusses considerations in the choice of initial ther-
apy and the agents available and under development for the
treatment of these infections.
Benefits of Prompt Appropriate Antibiotic Therapy 
for Serious Infections
Appropriate initial treatment of infections in the intensive
care unit reduces deaths
Inadequate treatment of infections in patients in the in-
tensive care unit (ICU) contributes to in-hospital death. A
1999 surveillance study of 2,000 consecutive eligible patients
with infections necessitating ICU admission found that the
hospital mortality rate in those receiving inadequate anti-
microbial treatment was significantly greater than that of pa-
tients without this risk factor (52.1% vs. 12.2%; relative risk
[RR] 4.26; 95% CI 3.52, 5.15; p  0.001) (Fig. 1) [3]. In this
study, oxacillin-resistant S. aureus was the most common
gram-positive bacterial pathogen isolated from individuals
receiving inadequate initial therapy [3]. Similar findings
were reported in patients with ventilator-associated pneu-
monia (VAP) [5] or sepsis [6]. A study of ICU patients found
that the higher mortality rate associated with inappropriate
initial therapy is still observed when antibiotics are switched
from an inappropriate to an appropriate agent [7].
Delayed appropriate treatment associated with longer
hospital stay
In addition to lowering the mortality rate, timely appro-
priate treatment may reduce hospital length of stay (LOS).
A study of 167 patients with S. aureus bacteremia found that
33.3% of patients with delayed appropriate treatment died
vs. 23% of patients who received early appropriate treatment
(p  0.05) [8]. In multivariable analyses, delayed treatment
was an independent predictor of infection-related death
(odds ratio [OR] 3.8; 95% CI 1.3, 11.0; p  0.01), and the ad-
justed mean LOS was longer in the delayed treatment than
the early treatment group (20.2 days vs. 14.3 days; p  0.05)
[8]. By logistic regression analysis, MRSA infection was the
most significant predictor of delayed appropriate treatment
(OR 8.3; 95% CI 2.6, 16.8); 42 of 48 episodes of delayed treat-
ment involved MRSA infection. Appropriate treatment was
delayed in these episodes because patients were treated ini-
tially with an antibiotic that lacked activity against the MRSA
strain [8].
Inappropriate treatment of CA-MRSA cSSTI associated
with treatment failure
In a retrospective study of 492 patients with community-
associated MRSA (CA-MRSA) SSTIs, 95% of the episodes
treated with an active antibiotic within 48 h were treated
successfully, compared with an 87% rate of successful treat-
ment in patients who did not receive an active antibiotic
(p  0.001) [4]. By logistic regression analysis, failure to ini-
tiate active antimicrobial therapy within 48 h of presenta-
tion was the only independent predictor of treatment 
failure (adjusted OR 2.80; 95% CI 1.26, 6.22; p  0.011) [4].
Similarly, in a study of patients admitted to the hospital with
MRSA sterile-site infection, multivariable analysis found in-
appropriate antimicrobial treatment to be an independent
risk factor for in-hospital death (adjusted OR 1.92; 95% CI
1.48, 2.50; p  0.013) [9].
An empiric treatment algorithm for SSTI in the setting of
escalating CA-MRSA was examined in emergency room pa-
tients. The algorithm promoted the use of antibiotics that are
likely active against CA-MRSA along with early incision and
drainage of abscesses. Clinical failure occurred in only 3% of
the patients treated according to the algorithm, compared
with 62% of those not so treated (p  0.001). Furthermore,
among patients who underwent immediate incision and
drainage, initial treatment with antibiotics active in vitro
against the MRSA isolate was associated with a lower clini-
cal failure rate than treatment with inactive antibiotics (0 vs.
67%; p  0.001) [10]. However, in one recent study of 117 pa-
tients with CA-MRSA and methicillin-sensitive S. aureus
(MSSA) skin infections, initial receipt of an antibiotic inac-
tive against the infecting strain did not predict non-response
to treatment at day 30 [11].
Considerations in Choice of Initial Therapy
Site and type of infection
The choice of empiric antimicrobial therapy for cSSTIs is
guided by a number of factors. In the case of surgical site in-
fection (SSI), the type and site of the surgical procedure dic-
tate which pathogens are suspected. Infections following 
surgery of the gastrointestinal or genitourinary tract may be
either monomicrobial or mixed, and may be caused by gram-
positive or gram-negative bacteria. By contrast, infections
following clean operations in other parts of the body typi-
cally are caused by gram-positive pathogens [12].
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FIG. 1. In 2,000 hospitalized patients with infections re-
quiring intensive care unit (ICU) admission, hospital mor-
tality rate of patients receiving inadequate antimicrobial
treatment was significantly greater than that of patients
without this risk factor (52.1% vs. 12.2%; relative risk [RR]
4.26; 95% confidence interval [CI] 3.52, 5.15; p  0.001). The
infection-related mortality rate also was statistically greater
among infected patients receiving inadequate antimicrobial
treatment (42.0%) than in infected patients receiving ade-
quate antimicrobial treatment (17.7%) (RR 2.37; 95% CI 1.83,
3.08; p  0.001) [3].
Certain community presentations of skin infection in-
creasingly are caused by MRSA, including impetigo and
necrotizing fasciitis [13]. Diabetic foot infections typically in-
volve S. aureus; other organisms may be present, but possi-
bly as colonizers, not pathogens [12].
Immunocompromised and neutropenic patients
Immunocompromised patients are, of course, at higher
risk of infection and less able to control local infection [13].
Immunocompromised or neutropenic patients should be
treated with empiric, broad-spectrum antibiotics at the first
clinical signs of infection, including fever [13]. Invasive skin
infections with CA-MRSA have been reported in solid organ
transplant recipients. These reports emphasize the clinical
importance of considering CA-MRSA as a causative patho-
gen in the differential diagnosis of cSSTIs in organ transplant
recipients [14].
In selecting empiric antibiotic therapy for skin infection in
neutropenic patients, consideration should be given to ade-
quate coverage against virulent and resistant gram-positive
organisms, including MRSA, vancomycin-resistant entero-
cocci (VRE), or penicillin-resistant Streptococcus pneumoniae.
Linezolid or daptomycin may be acceptable alternatives to
vancomycin [13].
Risk for HA-MRSA or CA-MRSA infection
All patients should be assessed for increased risk of 
hospital-acquired MRSA (HA-MRSA) and CA-MRSA skin
infection. Risk factors for HA-MRSA infection include isola-
tion of MRSA two or more days after hospitalization; a his-
tory of hospitalization, surgery, dialysis, or residence in a
long-term care facility within the previous year; the presence
of a permanent indwelling catheter or percutaneous medical
device; or previous isolation of MRSA [15].
Risk factors for CA-MRSA are less clear than those for HA-
MRSA. Outbreaks of skin infections caused by CA-MRSA
strains have been reported in community residents who lack
the typical risk factors for MRSA infection. These patients in-
clude prison inmates, injection drug users, Native American
populations, men who have sex with men, and children [13].
A list of persons at risk for SSTIs caused by CA-MRSA is
given in Table 1 [16]. Outbreaks of furunculosis caused by
CA-MSSA and by CA-MRSA may occur in families and in
other settings involving close personal contact, such as sports
teams. Inadequate personal hygiene and contact with in-
fected individuals are predisposing factors [13].
Initial broad-spectrum therapy and de-escalation
All patients who present with cSSTIs should receive
broad-spectrum antimicrobial therapy, including mandatory
coverage for MRSA. Patients who present to the hospital
with severe infection or infection progressing despite anti-
biotic therapy should be treated aggressively. In these cases,
if S. aureus is cultured, the clinician should assume the or-
ganism is resistant and administer an agent effective against
MRSA, such as vancomycin, linezolid, or daptomycin. Step-
down to other agents for MRSA infection, such as minocy-
cline or trimethoprim/sulfamethoxazole (TMP/SMX), may
be considered according to the susceptibility findings and
initial clinical response [13].
Choice of Treatment for MRSA cSSTI
The choice of treatment agent for MRSA cSSTI depends
on the type of infection and suspected pathogens [12]. Table
2 presents recommendations endorsed by the Infectious Dis-
eases Society of America (2005) for MRSA SSTI treatment in
adults [13].
HA-MRSA and CA-MRSA antibiotic susceptibilities
Neither CA-MRSA nor HA-MRSA can be treated with 
-lactam antibiotics. However, CA-MRSA tends to be suscep-
tible to more antibiotic classes than HA-MRSA. The former is
significantly more susceptible to ciprofloxacin, clindamycin,
and gentamicin, and slightly more susceptible to TMP/SMX,
than is HA-MRSA [17]. Community-acquired MRSA can be
treated with vancomycin, clindamycin, or TMP/SMX; addi-
tional agents are tetracycline, linezolid, and gentamicin [12].
Gentamicin should be used only in combination with other
agents [12], and some apparently clindamycin-susceptible
CA-MRSA strains develop resistance to the drug during ther-
apy [1]. Tigecycline may also be an option for hospitalized pa-
tients with CA-MRSA skin infection [12].
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TABLE 1. PERSONS AT RISK FOR SKIN AND SOFT TISSUE
INFECTIONS CAUSED BY COMMUNITY-ASSOCIATED
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
Household contacts of Intravenous drug users
patients with proven Incarcerated persons
CA-MRSA infection Athletes, particularly those
Children involved in contact sports
Day care center contacts of Native Americans
hospitalized patients Pacific Islanders
with MRSA infections Persons with previous
Men who have sex CA-MRSA infection
with men
Military personnel
Reproduced with permission from reference 16. Copyright © 2007
Massachusetts Medical Society. All rights reserved.
CA-MRSA  community-associated methicillin-resistant 
Staphylococcus aureus; MRSA  methicillin-resistant S. aureus.
TABLE 2. RECOMMENDED ANTIMICROBIAL THERAPY FOR SKIN
AND SOFT TISSUE INFECTIONS IN ADULTS CAUSED
BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUSa
Intravenous antibiotics
Vancomycin 30 mg/kg/d in two doses
Linezolid 600 mg q12h
Clindamycin 600 mg q8h
Daptomycin 4 mg/kg q24h
Oral antibiotics
Linezolid 600 mg bid
Clindamycin 300–450 mg tid
Doxycycline or minocycline 100 mg bid
Trimethoprim/ 1 or 2 double-strength
sulfamethoxazole tablets bid
aRecommendations endorsed by the Infectious Diseases Society of
America as of 2005.
Adapted from references 12 and 13.
In patients with presumed CA-MRSA SSTIs, it has been
recommended that uncomplicated infections in otherwise
healthy individuals be treated empirically with clindamycin,
TMP/SMX, or a tetracycline, although specific data from
multi-center randomized trials supporting the efficacy of
these treatments are lacking [18]. A recent single-center ran-
domized clinical trial compared TMP/SMX and doxycycline
for outpatient SSTIs in 34 patients requiring incision and
drainage and packing of abscesses, but not hospitalization
[19]. This study found an overall clinical failure rate of 9%,
with all failures occurring in the TMP/SMX group [19]. In
healthy patients with small purulent lesions, drainage alone
may be sufficient [1]. However, in patients with cSSTIs and
co-morbidities who require hospitalization, initial broad-
spectrum systemic antibiotic therapy should include specific
anti-MRSA activity.
Patients with HA-MRSA infection have a narrower range
of therapeutic options. The organism remains sensitive to
vancomycin, TMP/SMX, some tetracyclines, and linezolid.
Tigecycline and daptomycin also are options. Gentamicin re-
sistance is more common in HA-MRSA than CA-MRSA
strains, and most strains are resistant to clindamycin [12].
Antibiotics that stimulate or inhibit toxin production
Protein cytotoxins play an important role in the patho-
genesis of a variety of staphylococcal infections, and toxin
production should be considered when selecting an anti-
microbial agent for gram-positive pathogens [20]. As many
as 54% of CA-MRSA isolates have the Panton–Valentine
leukocidin (PVL) gene, encoding a virulence factor that
causes tissue necrosis and leukocyte destruction [21].
Whether PVL contributes to the pathogenesis of necrotiz-
ing SSTIs caused by MRSA, or is just a marker, remains to
be determined, although results obtained with CA-MRSA
isogenic PVL-deletion strains indicate that PVL does not
play a major role in CA-MRSA SSTIs [22]. A recently iden-
tified class of secreted staphylococcal peptides (phenol-sol-
uble modulin peptides) has a remarkable ability to recruit,
activate, and lyse human neutrophils, thus eliminating the
main cellular defense against MRSA [23]. The -lactam
agents actually enhance toxin production and may con-
tribute to worse outcomes in patients with MRSA infections
[20]. Linezolid, in contrast, has the ability to inhibit pro-
duction of PVL and toxic shock syndrome toxin [20].
Vancomycin and Newer Agents for MRSA Infection
There are four antibiotics approved by the U.S. Food and
Drug Administration (FDA) for the treatment of MRSA
cSSTIs: Vancomycin, linezolid, daptomycin, and tigecycline
[16]. Ceftobiprole and ceftaroline are anti-MRSA cephalo-
sporins under investigation for the treatment of complicated
skin and skin structure infections (cSSSIs). The glycopeptides
dalbavancin, telavancin, and oritavancin also are under in-
vestigation for treatment of cSSSIs, as is iclaprim, a di-
aminopyrimidine. Table 3 lists the results of clinical trials of
these agents in the treatment of MRSA cSSTIs.
Vancomycin
Vancomycin, a bactericidal glycopeptide, emerged as an
important antibiotic in the 1980s and 1990s with the rise of
MRSA infections [24]. Vancomycin has been the reference
standard for treating MRSA infections because of its relative
safety, its durability against the development of resistance,
and—until recently—the lack of other approved alternatives
for the treatment of MRSA [25]. However, vancomycin is be-
ing linked increasingly to clinical failures, possibly caused
by underdosing, poor tissue penetration, loss of accessory
gene-regulator function in the organism, slower bactericidal
effect, and escalation of vancomycin minimum inhibitory
concentrations (MICs) [25,26]. In a single-center review of
288 patients who required surgical intervention for cSSTIs
from 2000–2006 in Houston, TX, vancomycin MICs increased
in MRSA isolates. In 2003, 100% of the MRSA isolates from
SSTIs had vancomycin MICs  0.5 mcg/mL, whereas in
2006, 62% had vancomycin MICs  0.5 mcg/mL, with 7%
having an MIC of 1 mcg/mL and 31% having an MIC of 
2 mcg/mL [27].
Whereas vancomycin resistance is rare, there have been a
number of reports of vancomycin-intermediate and vanco-
mycin-resistant S. aureus dating to 1999 [25]. According to
the U.S. Centers for Disease Control and Prevention (CDC),
overuse of vancomycin and the accompanying emergence of
vancomycin resistance are cause for concern [28].
Vancomycin has a relatively low rate of tissue penetra-
tion [29–31], typically between 10% and 20%, sometimes re-
sulting in drug concentrations too low to be therapeutic
[29–31]. Vancomycin also has delayed penetration into skin
and soft tissues. Vancomycin concentrations in breast tis-
sues were evaluated in 24 women undergoing reconstruc-
tive surgery after mastectomy for breast cancer. Patients
were given a single prophylactic dose of vancomycin (1 g
IV) 1–8 h before surgery, and tissue concentrations were
measured by high performance liquid chromatography.
Vancomycin was not detectable in the majority of patients
at 1–3 h postdose [32].
Vancomycin concentrations in serum, tissue, and sternal
bone in patients receiving antimicrobial prophylaxis for
coronary artery bypass surgery also were examined. The
lowest drug concentrations (4.0–4.8 mcg/g) were found in
fat when the mean serum concentration was 55.1  22.8
mcg/mL. At 210 min after vancomycin dosing, the serum
concentration decreased to 16.2  4.6 mcg/mL, with fat con-
centrations ranging from 5.4–7.7 mcg/g and skin concentra-
tions ranging from 15.8–23.5 mcg/g, thus documenting 
delayed tissue penetration of vancomycin [33].
Vancomycin can trigger synergistic nephrotoxicity when
administered concurrently with other nephrotoxic agents,
and can cause ototoxicity [34]. Additionally, it must be ad-
ministered parenterally (except in colitis caused by Clostrid-
ium difficile) [34], which requires skilled nursing time for IV
catheter care, monitoring, and dosage adjustments.
Linezolid
After vancomycin, linezolid is the second-most-studied
agent for MRSA. Linezolid, first in the class of oxazolidi-
nones, offers broad-spectrum gram-positive activity with
100% oral bioavailability [35]. Linezolid has been approved
for the treatment of vancomycin-resistant Enterococcus fae-
cium infections, cSSSIs and nosocomial pneumonia caused
by MSSA and MRSA, and uncomplicated SSSIs and com-
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munity-acquired pneumonia caused by MSSA [35]. Line-
zolid has demonstrated excellent penetration of bone (60%,
when compared with simultaneous blood concentrations)
and muscle (94%) [36]. In addition, the drug has excellent
blister fluid penetration, a mean of 104%, representative of
soft tissue penetration [37].
Linezolid soft tissue penetration was examined against
strains of MRSA with reduced vancomycin susceptibility in
patients with diabetic foot infections [38]. Linezolid concen-
trations in tissue were found to be 51% of the simultaneous
serum concentrations. Rapid (1 h) and prolonged (12 h) in-
hibitory activity was observed against each of the study iso-
lates. Furthermore, bactericidal activity was observed for at
least 6 h (50% of the dosing interval) against four of the five
strains [38]. These findings suggest that linezolid could be
effective in the treatment of multi-drug-resistant MRSA,
even when the concentration at the infection site is dimin-
ished by impaired blood flow.
The 2006 LEADER surveillance program, which assessed
more than 5,000 clinical isolates from 50 medical centers
throughout the U.S., reported that more than 99.5% of gram-
positive organisms and more than 99.9% of S. aureus isolates
remain susceptible to linezolid [39]. Recent studies of nosoco-
mial pneumonia and VAP have suggested that linezolid may
yield significantly better clinical outcomes than vancomycin in
patients with serious infections resulting from MRSA [40,41].
In the largest cSSSI trial to date, 1,200 adult patients with
suspected or proved MRSA were randomized to treatment
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TABLE 3. CLINICAL TRIAL RESULTS FOR TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS
CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
Outcome in
MRSA Outcome in all
patients: patients:
Experimental Total agent vs. agent vs.
Antibiotic Comparator design patients No. of patients comparator comparator
Linezolid42a Vancomycin Open-label 1,180 285 Clinical cure43: Clinically evaluable:
94.0% vs. 83.6% 94.4% vs. 90.4%
Microbiol. cure:
88.6% vs. 66.9%
Daptomycin55a Vancomycin Double-blind 1,092 64 75.0% vs. 69.4% Clinically evaluable:
83.4% vs. 84.2%
Tigecycline61a Vancomycin Double-blind 1,116 65 Clinically evaluable:
86.5% vs. 88.6%
Dalbavancin68b Linezolid Double-blind 1,854 278 91% vs. 89% 88.9% vs. 91.2%
Telavancin72b Vancomycin Double-blind 1,867 579 Clinical cure: Clinically evaluable:
90.6% vs. 86.4% 88% vs. 87%
Microbiol. cure:
90% vs. 85%




Ceftobiprole62b Vancomycin  Double-blind 1,828 123 89.7% vs. 86.1% Clinical cure ITT:
ceftazidime (included 81.9% vs. 80.8%
diabetic foot Clinically evaluable:
infections) 90.5% vs. 90.2%
Iclaprim80b Linezolid Double-blind 1,497 70% of Clinical cure ITT:
pathogens were 85.5% vs. 91.9%
Staphylococcus Clinically evaluable:
aureus, 25% of 93.8% vs. 99.1%
which were Microbiol. cure:
MRSA 93.8% vs. 98.8%
Iclaprim80b Linezolid Double-blind 1,494 60% of Microbiol. cure Clinical cure ITT:
pathogens were MRSA: 84.9% vs. 87.2%
S. aureus, 50% 77.0% vs. 80.0% Clinically evaluable:






aFood and Drug Administration–approved for treatment of cSSTI caused by MRSA.
bInvestigational agent.
Microbiol.  microbiological; MRSA  methicillin-resistant Staphylococcus aureus; ITT  intent to treat; MSSA  methicillin-sensitive 
S. aureus; cSSTI  complicated skin and soft tissue infection.
with linezolid (IV or oral) or vancomycin (1 g q12h IV). For
the primary efficacy outcome, clinical response at the TOC
visit in the ITT population was 92.2% (439/476) for patients
treated with linezolid, compared with 88.5% (402/454) for
those treated with vancomycin (p  0.057); thus, the 2 drugs
were equivalent in this population (Fig. 2) [42]. For the sub-
groups with MRSA isolated at baseline in the modified
intent-to-treat (mITT) population (n  285) and in the micro-
biologically evaluable (ME) population (n  361), the clinical
success (cure) rate was better for linezolid-treated subjects
than for the vancomycin-treated subjects (mITT 92.0% vs.
81.8%; p  0.0114; ME 94.0% vs. 83.6%; p  0.0108) (Fig. 3)
[43]. The number of subjects with MRSA at baseline was sim-
ilar in the treatment groups [42]. In this study, microbiologic
eradication rates for linezolid (88.6%) vs. vancomycin (66.9%;
p  0.0001) were reported in patients with confirmed MRSA
(Fig. 3) [42]. An earlier study in patients with MRSA-com-
plicated surgical site infections also found that significantly
more patients treated with linezolid experienced microbio-
logic success (87%) than did patients treated with vancomy-
cin (48%; p  0.0022) [44].
Linezolid, which has a 100% bioavailable oral formulation,
has been associated with shorter LOS and duration of IV
treatment compared with vancomycin. A 2005 study found
that linezolid-treated patients with cSSSIs caused by sus-
pected or proved MRSA had a hospital LOS 2.5 days shorter
than vancomycin-treated patients [45]. A number of other
studies have confirmed the cost-effectiveness of linezolid vs.
vancomycin for hospitalized patients with cSSTIs [46–50].
In a study of the rates of antimicrobial susceptibility of S.
aureus from skin and wound infections reported from nine
regions of the U.S. during 2005–2007 from The Surveillance
Network, linezolid resistance was rare. Linezolid resistance
was reported in 13 of 80,527 isolates in 2007, although these
data have not been confirmed [51].
Linezolid is not active against gram-negative organisms
and appropriate antibiotic coverage should be administered
if gram-negative infections are known or suspected [35]. Lac-
tic acidosis has been reported in some patients [35]. Lactic
acidosis should be considered in any patient receiving line-
zolid who presents with nausea, vomiting, and a low serum
bicarbonate concentration [35]. Serotonin syndrome also is
possible when serotonergic agents, such as selective sero-
tonin reuptake inhibitors (SSRIs), are combined with line-
zolid [52]. When administering linezolid to patients taking
SSRIs, it is prudent to monitor for symptoms such as hy-
perpyrexia and mental status change [35]. Finally, periph-
eral and optic neuropathy can occur with linezolid, typically
after use for longer than three months [35].
Daptomycin
Daptomycin, a cyclic lipopeptide, is a potent bactericidal
agent that has shown no cross-resistance to date [53,54]. Dap-
tomycin is U.S. Food and Drug Administration (FDA)-
approved for the treatment of cSSSIs caused by gram-posi-
tive pathogens and for bacteremia but not for treatment of
pneumonia [54]. Although it is available in IV form only,
daptomycin may be administered to outpatients because of
its once-daily or every-other-day dosing.
An analysis of 902 evaluable patients from two random-
ized, multi-national trials demonstrated clinical equivalency
between daptomycin and conventional antibiotics (vanco-
mycin or penicillinase-resistant penicillins) in the treatment
of cSSSIs [55]. Clinical success rates in the clinically evalu-
able population were 83.4% for daptomycin-treated patients
and 84.2% for comparator-treated patients (95% CI 4.0, 5.6)
[55].
Only 64 patients with MRSA were evaluated microbio-
logically in the study cohort. Among patients with confirmed
MRSA infections, the clinical success rates were 75.0% for
daptomycin and 69.4% for the comparator drug (95% CI 
28.5, 17.4) [55]. The frequency, distribution, and severity of
adverse events (AEs) were similar for in the two treatment
groups [55].
The efficacy of daptomycin in cSSTIs also has been exam-
ined in the Cubicin Outcomes Registry and Experience 2004
Registry, a multi-center observational registry involving 
45 institutions. A total of 165 patients were identified, in-
cluding 145 with MRSA and 20 with MSSA cSSTIs, but with-
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FIG. 2. In the clinically evaluable population of the total
study cohort of 1,200 hospitalized adult patients with com-
plicated skin and soft tissue infections, clinical cure was
achieved in 94.4% (436/462) of patients treated with linezolid
compared with 90.4% (394/436) of patients treated with van-
comycin (p  0.023) [42].
FIG. 3. In microbiologically evaluable patients with methi-
cillin-resistant Staphylococcus aureus isolated as causative
pathogen for complicated skin and soft tissue infections, line-
zolid treatment was associated with higher clinical (94.0%
vs. 83.6%; p  0.0108) and microbiologic (88.6% vs. 66.9%;
p  0.0001) cure rates [42,43].
out bacteremia, endocarditis, osteomyelitis, or other major
infectious processes. Clinical success was achieved with 
daptomycin in 89.1% of patients overall, including 89.7% in
patients with MRSA. Prior antibiotic therapy had been ad-
ministered to 74.2% of patients and concomitant antibiotic
therapy to 39.4% [56].
Another study examined daptomycin efficacy in 53 adult
patients with cSSTIs at risk for MRSA infection compared
with a matched retrospective cohort of 212 patients treated
with vancomycin. The proportions of patients with clinical
improvement or resolution of their infections on days three
and five were 90% vs. 70% and 98% vs. 81% in the dapto-
mycin and vancomycin groups, respectively [57].
The serum creatine phosphokinase concentration should
be monitored weekly during use of daptomycin, especially
if high doses are given [54]. Caution is necessary in patients
previously treated with vancomycin, which may influence
daptomycin susceptibility [58].
Tigecycline
Tigecycline, approved in 2005, is the first agent of the 
glycylcycline class. Chemically similar to minocycline, tige-
cycline is better tolerated and more active against tetracy-
cline-resistant strains [59]. Tigecycline is effective over a
broader spectrum than many other agents, but does not
cover Pseudomonas aeruginosa or Proteus spp. [60]. In a study
of more than 500 gram-positive isolates, tigecycline inhibited
all strains, including those resistant to other tetracyclines
[59]. Its coverage includes VRE, penicillin-resistant S. pneu-
moniae, and MRSA [59].
In two phase 3, double-blind studies of hospitalized pa-
tients with cSSSIs, tigecycline demonstrated clinical cure
rates equivalent to those of vancomycin plus aztreonam
among the 833 clinically evaluable patients (86.5% vs. 88.6%,
respectively; 95% CI 6.8, 2.7) [61]. In these two registration
studies, only 65 patients with MRSA were ME [61]. Among
the ME patients with MRSA infection, the microbiologic
eradication rates were 78.1% for tigecycline-treated patients
and 75.8% for vancomycin-treated patients [61]. Each med-
ication regimen was well tolerated. More AEs related to the
digestive tract were reported in the tigecycline group, and
more rash, cardiovascular events, and increases in hepatic
aminotransferase concentrations were reported in the van-
comycin/aztreonam group [61]. In clinical trials, the most
frequent side effects associated with tigecycline were nausea
and vomiting [60].
Investigational cephalosporins
The cephalosporin ceftobiprole, which is not yet approved
by the FDA, is the first -lactam antibiotic to have activity
against MRSA, as well as penicillin-resistant streptococci.
Ceftobiprole has shown low potential to select for resistance
[25]. The drug also appears to have clinically relevant activ-
ity against gram-negative bacteria [62]. In testing against 100
CA-MRSA and 100 HA-MRSA isolates, the documented
MIC50/MIC90 values were 0.5 mcg/mL against both types.
In time–kill analysis, ceftobiprole was bactericidal at all con-
centrations tested [63].
In a randomized, multi-center, global, double-blind trial
comparing ceftobiprole with vancomycin plus ceftazidime in
729 clinically evaluable patients with cSSSIs (including dia-
betic foot infections), the clinical cure rate at the TOC was
90.5% for ceftobiprole-treated and 90.2% for comparator-
treated patients (95% CI 4.2, 4.9) [62]. In patients with
MRSA infection, the clinical cure rate was 89.7% for 
ceftobiprole-treated and 86.1% for comparator-treated pa-
tients (95% CI 8.0, 19.7) [62]. Ceftobiprole was well-toler-
ated, and the incidence of serious AEs was similar in the two 
treatment groups [62].
A second global, randomized, double-blind trial com-
pared the efficacy of ceftobiprole with that of vancomycin in
patients with cSSTIs caused by gram-positive bacteria [64].
The primary objective was to assess non-inferiority on the
basis of the cure rate seven to 14 days after the completion
of therapy in patients receiving ceftobiprole 500 mg q12h or
vancomycin 1 g q12h. Of 784 patients randomized, 282 who
received ceftobiprole and 277 who received vancomycin
were evaluable clinically. Of these patients, 93.3% treated
with ceftobiprole and 93.5% treated with vancomycin were
cured (95% CI 4.4, 3.9). The cure rates for patients with
MRSA infections were 91.8% (56/61) with ceftobiprole and
90.0% (54/60) with vancomycin (95% CI 8.4, 12.1) [64]. At
least one AE was reported by 52% of the ceftobiprole-treated
patients and 51% of the vancomycin-treated patients. The
most common AEs reported by the ceftobiprole-treated 
patients were nausea (14%) and taste disturbance (8%). 
Discontinuation of the study drug because of treatment-
associated AEs occurred in 4% (n  17) of the ceftobiprole-
treated patients and 6% (n  22) of the vancomycin-treated
patients [64].
The results of these two trials support the use of cefto-
biprole as a treatment option for patients with cSSSIs caused
by a spectrum of gram-positive bacteria. Ceftobiprole has re-
ceived fast-track designation from the FDA for the treatment
of cSSSIs caused by MRSA, with an additional designation
for the treatment of hospital-acquired pneumonia and VAP
caused by proved or suspected MRSA [65]. In March, 2008,
the FDA issued a letter requesting additional information for
ceftobiprole in the treatment of cSSTIs, including diabetic
foot infections. According to Basilea Pharmaceutica, FDA ap-
proval is subject to clinical study site inspections, the as-
sessment of clinical and microbiological data, “and further
characterization of patients with diabetic foot infections”
[66].
Ceftaroline, another investigational anti-MRSA cephalo-
sporin with broad-spectrum coverage for gram-negative and
gram-positive pathogens, is under investigation for cSSSIs
[25]. In a phase 2 study, the clinical cure rate in the clinically
evaluable population was 96.7% for ceftaroline-treated pa-
tients and 88.9% for patients receiving vancomycin with or
without aztreonam [67]. Among the ME subjects, the micro-
biological success rate was 95.2% for ceftaroline vs. 85.7% for
vancomycin. Ceftaroline exhibited a favorable safety and tol-
erability profile, consistent with that of marketed cephalo-
sporins [67].
Investigational glycopeptides
There are three anti-MRSA IV glycopeptides in late de-
velopment: Dalbavancin, telavancin, and oritavancin.
Dalbavancin. The unique feature of dalbavancin is its 
extraordinarily long half-life (6–10 days), which allows once-
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weekly dosing [25]. In a phase 3 trial, IV dalbavancin, ad-
ministered on day 1 and day 8, was compared with IV/oral
linezolid, given twice daily for 14 days, in 660 clinically
evaluable patients with cSSSIs [68]. At the TOC visit, 88.9%
of the dalbavancin-treated patients and 91.2% of the line-
zolid-treated patients had achieved clinical success [68]. The
rates of MRSA eradication in 278 patients with confirmed
MRSA cSSTIs were 91% in the dalbavancin group and 89%
in the linezolid group [68]. The safety profiles for the two
agents were similar [68].
Telavancin. Telavancin is a semisynthetic lipoglycopep-
tide with a dual mechanism of action: Inhibition of cell wall
synthesis and disruption of membrane barrier function. It
has a 7- to 9-h half-life, which allows once-daily dosing. Tela-
vancin is under investigation for the treatment of cSSTIs,
nosocomial pneumonia, and uncomplicated bacteremia
caused by S. aureus [25]. In two phase 2 trials for treatment
of cSSTIs, similar clinical success rates were achieved in pa-
tients receiving telavancin or standard therapy for infections
caused by S. aureus and MRSA [69,70].
Two parallel, randomized, double-blind, active-control,
phase 3 studies with a pre-specified pooled analysis design
were conducted in patients aged 18 years or older who had
cSSTIs caused by suspected or confirmed gram-positive or-
ganisms [71]. Patients were randomized to receive either
telavancin (10 mg/kg IV q24h) or vancomycin (1 g IV q12h).
A total of 1,867 patients were randomized and received at
least one dose of study medication. In the clinically evalu-
able population, at 7–14 days after receipt of the last antibi-
otic dose, success was achieved in 88% and 87% of patients
who received telavancin and vancomycin, respectively (95%
CI 2.1, 4.6) [71].
Methicillin-resistant S. aureus was isolated at baseline from
samples from 579 clinically evaluable patients—the largest se-
ries to date. Among these patients, the cure rate was 91%
among patients who received telavancin and 86% among 
patients who received vancomycin (95% CI 1.1, 9.3). Micro-
biologic eradication of MRSA was achieved in 90% of the tela-
vancin group and 85% of the vancomycin group (95% CI 0.9,
9.8). This study confirmed that telavancin given once daily is
at least as effective as vancomycin for the treatment of patients
with cSSTIs, including those infected with MRSA [71].
Therapy was discontinued because of AEs in 8% and 6%
of patients who received telavancin and vancomycin, re-
spectively. Except for mild taste disturbance, nausea, vom-
iting, and serum creatinine concentration elevation in the
telavancin treatment group and pruritus in the vancomycin
treatment group, the AEs were similar in the two groups
with regard to type and severity [71].
Oritavancin. Oritavancin is another broad-spectrum semi-
synthetic glycopeptide under development for the treatment
of cSSTIs, catheter-related blood stream infections, and noso-
comial pneumonia [25]. It has demonstrated activity against
vancomycin-resistant strains of staphylococci and entero-
cocci [25] and has a long half-life (100 h), which is expected
to allow once-daily or every-other-day dosing. The manu-
facturer reports that two phase 3 trials for treatment of 
cSSTIs have been completed, with the primary endpoints be-
ing met in each [72,73,74].
Iclaprim
Iclaprim, an agent under investigation, is a diaminopy-
rimidine with activity against MRSA [25]. The manufacturer
reports that in two phase 3 trials for the treatment of cSSTIs,
iclaprim achieved its primary efficacy endpoint and had a
safety profile similar to that of the comparator, linezolid [75].
The multi-center, double-blind, randomized, active-control,
parallel-assignment, phase 3 trial, ASSIST-1 (Arpida’s Skin
and Skin Structure Infection Study), compared IV iclaprim
(0.8 mg/kg; N  250) with IV linezolid (600 mg; N  247),
both administered for 10 to 14 days, in patients with cSSTI
who had extensive cellulitis, abscesses, ulcers, burns, or
wounds [76,77]. The primary objective was to compare the
clinical cure rates of iclaprim and linezolid at the TOC visit
[77]. Secondary outcomes included clinical efficacy at the end
of the trial and clinical outcomes of the ME and ITT popu-
lations [77]. Approximately 70% of the pathogens isolated at
baseline were S. aureus, 25% of which were MRSA [77]. For
the ME patients, the cure rates were 94.7% and 98.8% for
iclaprim and linezolid, respectively. Non-inferiority was
achieved for the primary endpoint, and the overall clinical
cure rate for the ITT population at the TOC was 85.5% and
91.9% for iclaprim and linezolid, respectively. The clinically
evaluable patients had cure rates of 93.8% and 99.1%, re-
spectively [77].
A subsequent multi-center, double-blind, randomized, ac-
tive-control, parallel-assignment phase 3 clinical trial, 
ASSIST-2, was initiated in cSSTI patients with extensive cel-
lulitis, abscesses, ulcers, burns, or wounds to compare IV
iclaprim (n  251) with IV linezolid (n  243) [77,78]. The
primary and secondary endpoints were the same as those in
the ASSIST-1 trial. Preliminary analysis indicated overall
clinical cure rates for the ITT population of 84.9% and 87.2%
for iclaprim and linezolid, respectively [77]. The most com-
mon baseline pathogen was S. aureus (60%), 50% of which
were MRSA. The microbiological eradication rates for MSSA
were 83.5% and 84.7% for iclaprim and linezolid, respec-
tively, and 77.0% and 80.0% for MRSA, respectively [77]. For
patients with gram-positive pathogen infections at baseline,
the clinical cure rates were 83.3% and 85.9% for iclaprim and
linezolid, respectively. In a preliminary analysis of the clin-
ically evaluable population, the cure rates were 89.6% and
96.4% for iclaprim and linezolid, respectively [77]. Further
analysis of the trial results is ongoing [77,78].
Conclusions
Inadequate treatment of severe infections in hospitalized
patients contributes to in-hospital death and prolonged LOS.
Prompt, appropriate treatment of cSSTIs caused by MRSA
increases the chances of a successful outcome. The choice of
antimicrobial agent for empiric treatment of cSSTI should be
guided by a number of considerations, including the site and
type of infection, presence of immunocompromised state or
neutropenia, and risk factors for HA-MRSA or CA-MRSA in-
fection. Patients with severe infection or co-morbidities
should be treated aggressively with empiric broad-spectrum
antimicrobial therapy and then de-escalated to narrower-
spectrum agents depending on the culture findings and 
clinical response. It is of paramount importance to obtain
specimens for culture and antimicrobial susceptibilities
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given the high prevalence of MRSA as a causative pathogen
in cSSTIs.
Community-associated MRSA infections are susceptible to
more antibiotics than HA-MRSA infections, which com-
monly are multi-drug-resistant. Most CA-MRSA strains
remain susceptible to ciprofloxacin, clindamycin, gentam-
icin, and TMP/SMX, although resistance to clindamycin can
emerge during treatment. Hospital-acquired MRSA is sus-
ceptible to fewer antibiotics. Of the agents available cur-
rently, vancomycin has been the reference standard, but 
increasing clinical failures have been reported—likely as a
result of poor tissue penetration and increasing MICs. Al-
ternative agents for the treatment of HA-MRSA include 
linezolid, daptomycin, and tigecycline, which have been
well-studied and are approved by the FDA for the treatment
of cSSTIs. A number of other antibiotic agents are under de-
velopment for the treatment of cSSTIs caused by MRSA.
References
1. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA; Partici-
pants in the CDC-Convened Experts’ Meeting on Manage-
ment of MRSA in the Community. Strategies for clinical
management of MRSA in the community: Summary of an
experts’ meeting convened by the Centers for Disease Con-
trol and Prevention. 2006. Available at http://198.246.98.21/
ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf.
Accessed March 10, 2008. (//www.cdc.gov/ncidod/dhqp/
ar_mrsa_ca_04meeting.html.)
2. Kuo DC, Chasm RM, Witting MD. Emergency department
physician ability to predict methicillin-resistant Staphylococ-
cus aureus skin and soft tissue infections. J Emerg Med 2008
May 29 [Epub ahead of print].
3. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate anti-
microbial treatment of infections: A risk factor for hospital
mortality among critically ill patients. Chest 1999;115:
462–474.
4. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-on-
set methicillin-resistant Staphylococcus aureus skin and soft-
tissue infections: Impact of antimicrobial therapy on out-
come. Clin Infect Dis 2007;44:777–784.
5. Iregui M, Ward S, Sherman G, et al. Clinical importance of
delays in the initiation of appropriate antibiotic treatment for
ventilator-associated pneumonia. Chest 2002;122:262–268.
6. Garnacho-Montero J. Impact of adequate empirical antibi-
otic therapy on the outcome of patients admitted to the in-
tensive care unit with sepsis. Crit Care Med 2003;31:
2742–2751.
7. Alvarez-Lerma F; ICU-Acquired Pneumonia Study Group.
Modification of empiric antibiotic treatment in patients with
pneumonia acquired in the intensive care unit. Intensive
Care Med 1996;22:387–394.
8. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes
analysis of delayed antibiotic treatment for hospital-ac-
quired Staphylococcus aureus bacteremia. Clin Infect Dis
2003;36:1418–1423.
9. Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-re-
sistant Staphylococcus aureus sterile-site infection: The im-
portance of appropriate initial antimicrobial treatment. Crit
Care Med 2006;34:2069–2074.
10. Chuck EA, Frazee BW, Lambert L, McCabe R. The benefit
of empiric treatment for methicillin-resistant Staphylococcus
aureus. J Emerg Med 2008 May 29 [Epub ahead of print]
11. Miller LG, Quan C, Shay A, et al. A prospective investigation
of outcomes after hospital discharge for endemic, community-
acquired methicillin-resistant and -susceptible Staphylococcus
aureus skin infection. Clin Infect Dis 2007;44:483–492.
12. Merlino JI, Malangoni MA. Complicated skin and soft-tis-
sue infections: Diagnostic approach and empiric treatment
options. Cleve Clin J Med 2007;74(Suppl 4):S21–S28.
13. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Dis-
eases Society of America. Practice guidelines for the diag-
nosis and management of skin and soft-tissue infections.
Clin Infect Dis 2005;41:1373–1406.
14. Adeyemi OA, Qi C, Zembower TR, et al. Invasive infections
with community-associated methicillin-resistant Staphylo-
coccus aureus after kidney transplantation. J Clin Microbiol
2008;46:2809–2813.
15. Fridkin SK, Hageman JC, Morrison M, et al; Active Bacte-
rial Core Surveillance Program of the Emerging Infections
Program Network. Methicillin-resistant Staphylococcus au-
reus disease in three communities. N Engl J Med 2005;352:
1436–1444.
16. Daum RS. Skin and soft-tissue infections caused by methi-
cillin resistant Staphylococcus aureus. N Engl J Med 2007;
357:380-390.
17. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of
community- and health care-associated methicillin-resistant
Staphylococcus aureus infection. JAMA 2003;290:2976–2984.
18. Stryjewski ME, Chambers HF. Skin and soft-tissue infec-
tions caused by community-acquired methicillin-resistant
Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl):
S368–S377.
19. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized
trial of empiric therapy with trimethoprim-sulfamethoxa-
zole or doxycycline for outpatient skin and soft tissue in-
fections in an area of high prevalence of methicillin-resistant
Staphylococcus aureus. Antimicrob Agents Chemother 2007;
51:2628–2630.
20. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on
expression of virulence-associated exotoxin genes in methi-
cillin-sensitive and methicillin-resistant Staphylococcus au-
reus. J Infect Dis 2007;195:202–211.
21. Davis SL, Perri MB, Donabedian SM, et al. Epidemiology
and outcomes of community-associated methicillin-resistant
Staphylococcus aureus infection. J Clin Microbiol 2007;45:
1705–1711.
22. Voyich JM, Otto M, Mathema B, et al. Is Panton–Valentine
leukocidin the major virulence determinant in community-
associated methicillin-resistant Staphylococcus aureus dis-
ease? J Infect Dis 2006;194:1761–1770.
23. Wang R, Braughton KR, Kretschmer D, et al. Identification
of novel cytolytic peptides as key virulence determinants
for community-associated MRSA. Nat Med 2007;13:
1418–1420.
24. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage
of vancomycin. Antimicrob Agents Chemother 1998;42:
1303–1304.
25. Micek ST. Alternatives to vancomycin for the treatment of
methicillin-resistant Staphylococcus aureus infections. Clin In-
fect Dis 2007;45:S184–190.
26. Stevens DL. The role of vancomycin in the treatment para-
digm. Clin Infect Dis 2006;42(suppl 1):S51–S57.
27. Awad SS, Elhabash SI, Lee L, et al. Increasing incidence of
methicillin-resistant Staphylococcus aureus skin and soft-tis-
sue infections: Reconsideration of empiric antimicrobial
therapy. Am J Surg 2007;194:606–610.
EARLY TREATMENT OF MRSA cSSTIs S-25
28. Centers for Disease Control and Prevention. 12 Steps to Pre-
vent Antimicrobial Resistance among Hospitalized Adults.
CDC Campaign to Prevent Antimicrobial Resistance in
Healthcare Settings. Available at http://www.cdc.gov/drug
resistance/healthcare/ha/12steps_HA.htm. Accessed Au-
gust 2, 2006.
29. Daschner FD, Frank U, Kümmel A, et al. Pharmacokinetcs
of vancomycin in serum and tissue of patients undergoing
open-heart surgery. J Antimicrob Chemother 1987;19:
359–362.
30. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of van-
comycin into human lung tissue. J Antimicrob Chemother
1996;38:865–869.
31. Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin
concentrations in infected and noninfected human bone. An-
timicrob Agents Chemother 1988;32:1320–1322.
32. Luzzati R, Sanna A, Allegranzi B, et al. Pharmacokinetics
and tissue penetration of vancomycin in patients undergo-
ing prosthetic mammary surgery. J Antimicrob Chemother
2000;45:243–245.
33. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics of
vancomycin administered as prophylaxis before cardiac sur-
gery. Therapeutic Drug Monit 2000;22:661–667.
34. Vancocin [package insert]. Exton, PA. ViroPharma Inc. 2005.
35. Zyvox [package insert]. New York, NY. Pfizer Inc. 2007.
36. Lovering AM, Zhang J, Bannister GC, et al. Penetration of
linezolid into bone, fat, muscle and haematoma of patients
undergoing routine hip replacement. J Antimicrob Chemo-
ther 2002;50:73–77.
37. Gee T, Ellis R, Marshall G, et al. Pharmacokinetics and tis-
sue penetration of linezolid following multiple oral doses.
Antimicrob Agents Chemother 2001;45:1843–1846.
38. Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue
penetration and serum activity against strains of methicillin-
resistant Staphylococcus aureus with reduced vancomycin
susceptibility in diabetic patients with foot infections. J An-
timicrob Chemother 2007;60:819–823.
39. Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveil-
lance program results for 2006: An activity and spectrum
analysis of linezolid using clinical isolates from the United
States (50 medical centers). Diagn Microbiol Infect Dis
2007;59:309–317.
40. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs
vancomycin: Analysis of two double-blind studies of pa-
tients with methicillin-resistant Staphylococcus aureus noso-
comial pneumonia. Chest 2003;124:1789–1797.
41. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and
survival in gram-positive ventilator-associated pneumonia:
Retrospective analysis of two double-blind studies compar-
ing linezolid with vancomycin. Intensive Care Med
2004;30:388–394.
42. Weigelt J, Itani K, Stevens D, et al; Linezolid CSSTI Study
Group. Linezolid versus vancomycin in treatment of com-
plicated skin and soft tissue infections. Antimicrob Agents
Chemother 2005;49:2260–2266.
43. Weigelt J, Itani K, Stevens D, Knirsch C. Is linezolid supe-
rior to vancomycin for complicated skin and soft tissue in-
fections due to methicillin-resistant Staphylococcus aureus?
Antimicrob Agents Chemother 2006;50:1910–1911.
44. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid
eradicates MRSA better than vancomycin from surgical-site
infections. Am J Surg 2004;188:760–766.
45. Itani KMF, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces
length of stay and duration of intravenous treatment com-
pared with vancomycin for complicated skin and soft tissue
infections due to suspected or proven methicillin-resistant
Staphylococcus aureus (MRSA). Int J Antimicrob Agents
2005;26:442–448.
46. Schürmann D, Sorensen SV, De Cock E, et al. Cost-effec-
tiveness of linezolid versus vancomycin for hospitalised pa-
tients with complicated skin and soft-tissue infections in
Germany. Eur J Health Econ 2008 Apr 24 [Epub ahead of
print].
47. McCollum M, Sorensen SV, Liu LZ. A comparison of costs
and hospital length of stay associated with intravenous/oral
linezolid or intravenous vancomycin treatment of compli-
cated skin and soft-tissue infections caused by suspected or
confirmed methicillin-resistant Staphylococcus aureus in el-
derly US patients. Clin Ther 2007;29:469–477.
48. McKinnon PS, Sorensen SV, Liu LZ, Itani KMF. Impact of
linezolid on economic outcomes and determinants of cost in
a clinical trial evaluating patients with MRSA complicated
skin and soft-tissue infections. Ann Pharmacother 2006;40:
1017–1023.
49. Sharpe JN, Shively, Polk HC Jr. Clinical and economic out-
comes of oral linezolid versus intravenous vancomycin in
the treatment of MRSA-complicated, lower-extremity skin
and soft-tissue infections caused by methicillin-resistant
Staphylococcus aureus (MRSA). Am J Surg 2005;189:425–428.
50. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid
versus vancomycin on length of hospital stay in patients with
complicated skin and soft tissue infections caused by known
or suspected methicillin-resistant staphylococci: Results from
a randomized clinical trial. Surg Infect 2003;4:57–70.
51. Tillotson GS, Draghi DC, Sahm DF, et al. Susceptibility of
Staphylococcus aureus isolated from skin and wound infec-
tions in the United States 2005–07: Laboratory-based sur-
veillance study. J Antimicrob Chemother 2008;62:109–115.
52. Narita M et al. Linezolid-associated peripheral and optic
neuropathy, lactic acidosis, and serotonin syndrome. Phar-
macotherapy 2007;27:1189–1197.
53. Owens RC Jr, Lamp KC, Friedrich LV, Russo R. Postmar-
keting clinical experience in patients with skin and skin-
structure infections treated with daptomycin. Am J Med
2007;120(10 suppl 1):S6–S12.
54. Cubicin [package insert]. Lexington, MA. Cubist Pharma-
ceuticals, Inc. 2007.
55. Arbeit RD, Maki D, Tally FP, et al.; Daptomycin 98-01 and
99-01 Investigators. The safety and efficacy of daptomycin
for the treatment of complicated skin and skin-structure in-
fections. Clin Infect Dis 2004;38:1673–1681.
56. Martone WJ, Lamp KC. Efficacy of daptomycin in skin and
skin-structure infections due to methicillin-sensitive and -re-
sistant Staphylococcus aureus: Results from the CORE Reg-
istry. Curr Med Res Opin 2006;22:2337–2343.
57. Davis SL, McKinnon PS, Hall LM, et al. Daptomycin versus
vancomycin for complicated skin and skin structure infec-
tions: Clinical and economic outcomes. Pharmacotherapy
2007;27:1611–1618.
58. Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction
of daptomycin heterogeneous susceptibility in Staphylococ-
cus aureus by exposure to vancomycin. Antimicrob Agents
Chemother 2006;50:1581–1585.
59. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro ac-
tivities of the glycylcycline GAR-936 against gram-positive
bacteria. Antimicrob Agents Chemother 2000;44:2225–2229.
60. Tygacil [package insert]. Philadelphia, PA. Wyeth Pharma-
ceuticals Inc. 2007.
NAPOLITANOS-26
61. Ellis-Grosse EJ, Babinchak T, Dartois N, et al.; Tigecycline
300 and 305 cSSSI Study Groups. The efficacy and safety of
tigecycline in the treatment of skin and skin-structure in-
fections: Results of 2 double-blind phase 3 comparison stud-
ies with vancomycin-aztreonam. Clin Infect Dis 2005;
41(suppl 5):S341–S353.
62. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-
blind trial comparing ceftobiprole medocaril with vanco-
mycin plus ceftazidime for the treatment of patients with
complicated skin and skin-structure infections. Clin Infect
Dis 2008;46:647–655.
63. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobi-
prole, linezolid, vancomycin, and daptomycin against com-
munity-associated and hospital-associated methicillin-resis-
tant Staphylococcus aureus. Antimicrob Agents Chemother
2008;52:2974–2976.
64. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-
blind, randomized trial of ceftobiprole treatment of compli-
cated skin and skin structure infections caused by gram-pos-
itive bacteria. Antimicrob Agents Chemother 2008;52:37-44.
65. Ceftobiprole (BAL5788) [Web site]. Basel, Switzerland:
Basilea Pharmaceutica Ltd; 2008. Available at http://
www.basilea.com/template_loader.php?tplpage_id19&_f
unctionrender&id1. Accessed January 3, 2008.
66. FDA issues approvable letter for ceftobiprole, a new anti-MRSA
broad-spectrum antibiotic [press release]. Basel, Switzerland:
Basilea Pharmaceutica Ltd; March 18, 2008. Available at
http://www.basilea.com/template_loader.php?tplpage_
id34&modedetails&id172. Accessed June 17, 2008.
67. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaro-
line versus standard therapy in treatment of complicated
skin and skin structure infections. Antimicrob Agents
Chemother 2007;51:3612–3616.
68. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, dou-
ble-blind comparison of once-weekly dalbavancin versus
twice-daily linezolid therapy for the treatment of compli-
cated skin and skin structure infections. Clin Infect Dis
2005;41:1407–1415.
69. Stryjewski ME, O’Riordan WD, Lau WK, et al.; FAST In-
vestigator Group. Telavancin versus standard therapy for
treatment of complicated skin and soft-tissue infections due
to gram-positive bacteria. Clin Infect Dis 2005;40:1601–1607.
70. Stryjewski ME, Chu VH, O’Riordan WD, et al.; FAST 2 In-
vestigator Group. Telavancin versus standard therapy for
treatment of complicated skin and skin structure infections
caused by gram-positive bacteria: FAST 2 study. Antimicrob
Agents Chemother 2006;50:862–867.
71. Stryjewski ME, Graham DR, Wilson SE, et al. on behalf of
the Assessment of Telavancin in Complicated Skin and Skin-
Structure Infections Study. Telavancin versus vancomycin
for the treatment of complicated skin and skin-structure in-
fections caused by gram-positive organisms. Clin Infect Dis
2008;46:1683–1693.
72. Targanta Therapeutics. Pipeline: Oritavancin program [Tar-
ganta.com Web site]. Available at http://www.targanta.
com/pipeline/oritavancin.html. Accessed June 18, 2008.
73. Giamarellou H, O’Riordan W, Harris H, Owen S, Porter S,
Loutit J. Phase 3 trial comparing 3–7 days of oritavancin vs.
10–14 days of vancomycin/cephalexin in the treatment of
patients with complicated skin and skin structure infections
(cSSSI) [abstract]. Presented at: 43rd Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC); Sep-
tember 14–17, 2003; Chicago, IL. Abstract L–739a.
74. Wasilewski MM, Disch DP, McGill JM, Harris HW, O’Rior-
dan W, Zeckel ML. Equivalence of shorter course therapy
with oritavancin vs. vancomycin/cephalexin in complicated
skin/skin structure infections (CSSI) [abstract]. Presented at:
41st Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC); December 16–19, 2001; Chicago,
IL. Abstract UL–18.
75. Arpida provides comprehensive overview of pivotal phase
III trial data [press release]. Reinach, Switzerland: Arpida
Ltd.; April 17, 2008. Available at http://www.arpida.
ch/users/1/content/arpida-assist-overview.pdf. Accessed
April 18, 2008.
76. Arpida’s Skin and Skin Structure Infection Study 1 (ASSIST-
1). Phase 3 safety and efficacy study of IV iclaprim vs line-
zolid in cSSSI (ASSIST-1). Available at http://clinicaltrials.
gov/ct2/show/NCT00299520?termiclaprimANDskin
&rank1. Accessed June 18, 2008.
77. Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine
dihydrofolate reductase inhibitor for the potential treatment
of antibiotic-resistant staphylococcal infections. Curr Opin
Invest Drugs 2008;9:210–225.
78. Arpida’s Skin and Skin Structure Infection Study 2 (ASSIST-
2). Study of intravenous (IV) iclaprim versus linezolid in
complicated skin and skin structure infections [cSSSI] (AS-
SIST-2). Available at http://clinicaltrials.gov/ct2/show/
NCT00303550. Accessed June 18, 2008.
Address reprint requests to:
Dr. Lena M. Napolitano
Department of Surgery
University of Michigan Health System
Room 1C421, University Hospital
1500 East Medical Center Dr.
Ann Arbor, MI 48109-0033
E-mail: lenan@umich.edu
EARLY TREATMENT OF MRSA cSSTIs S-27
